Navigation Links
CoolTouch Inc. Settles Diomed Lawsuit, Files Re-examination Request for Cynosure '873 Patent
Date:4/13/2009

ROSEVILLE, Calif., April 13 /PRNewswire/ -- On April 7, 2009, the Boston District Court dismissed the "Diomed" lawsuit between Endolaser Associates, LLC and CoolTouch Inc. after CoolTouch signed a settlement agreement with Dr. Luis Navarro. This patent infringement suit was originally filed in 2004 and relates to the use of lasers for endovenous ablation. CoolTouch will license the '777 Navarro patent and pay royalties on CTEV laser sales and accessories that potentially allow vein wall contact with the emitting part of the fiber.

CoolTouch CEO David R. Hennings states, "We have reached an agreement that recognizes the inventor's pioneering work in the field of endovenous laser ablation and makes business sense for CoolTouch."

In another patent matter, CoolTouch, working with the Boston law firm of McCarter & English LLP, has filed a re-examination request with the U.S. Patent Office of the '873 Paolini laser lipolysis patent assigned to Cynosure, which is the subject of litigation between the parties. CoolTouch requests the re-examination based on prior art by Dr. David Apfelberg and by Mr. David Hennings. CoolTouch has filed for a stay in the litigation until the patent office rules on the validity of this patent. Over 70% of re-examinations by the Patent Office result in claim rejections.

Until the stay is accepted, CoolTouch is confident that the court will also rule in its favor on the issue of non-infringement. On Dec. 22, 2008, the court's Markman ruling rejected Cynosure's attempts to define "adjacent" to mean "in the vicinity of" the tip of the needle. The court said that "adjacent" means "next to" the tip of the needle. The CoolTouch CoolLipo(TM) device uses a fiber that extends 5mm beyond the tip of the cannula and is clearly not "next to" the tip of the cannula.

Recently, the patent office has published two new CoolTouch patent applications that relate to laser-assisted lipolysis. These new patent applications are continuations-in-part of issued patent No. 7,217,265 filed in May 2005, and cover laser lipolysis devices such as thermal sensing, suction handpieces and placement of the fiber optic in direct contact with the tissue.

About CoolTouch

CoolTouch Inc. is a leading U.S.-based developer and manufacturer of innovative, advanced laser products for medical professionals. Engineering and science-based, CoolTouch is considered a pioneer in the medical and aesthetics technology industry. In 1994, CoolTouch introduced the first 1320 nm wavelength laser to medical professionals for non-ablative wrinkle treatment. CoolTouch continued to set new standards in the industry with the launch of CoolTouch CTEV in 2004 for varicose vein treatment and with CoolLipo for laser lipolysis and skin tightening in 2007. CoolTouch products are FDA-cleared and are manufactured in Roseville, Calif. For more information: www.cooltouch.com


'/>"/>
SOURCE CoolTouch Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CoolTouch Introduces CoolLipo(TM) Laser System, Recently FDA Cleared for Laser-Assisted Lipolysis
2. Cynosure Files Patent Infringement Lawsuit Against CoolTouch Inc.
3. CoolTouch Inc. Responds to Cynosure Patent Infringement Lawsuit
4. CoolTouch Introduces CoolBlue Duet(TM) Laser Lipolysis Suction Handpiece
5. VNUS Medical Technologies, Inc. Files Patent Infringement Lawsuits Against Biolitec, Dornier and CoolTouch
6. CoolTouch Launches CoolLipo Trio Offering Physicians Three Functions in One
7. Cynosure Obtains Favorable Markman Rulings in Patent Infringement Case Against CoolTouch
8. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
9. Sunrise Settles Litigation Regarding Its 2007 Annual Meeting
10. Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter
11. Novo Nordisk Settles With Pfizer On Patent Infringement Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: